{"id":17577,"date":"2026-07-07T09:23:49","date_gmt":"2026-07-07T09:23:49","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=webinar-and-podcast&p=17577"},"modified":"2026-07-15T10:56:10","modified_gmt":"2026-07-15T10:56:10","slug":"ai-meets-expertise-a-hybrid-workflow-for-modern-target-id-qiagen-sygnature","status":"publish","type":"webinar-and-podcast","link":"https:\/\/www.sygnaturediscovery.com\/fr\/webinar-and-podcast\/ai-meets-expertise-a-hybrid-workflow-for-modern-target-id-qiagen-sygnature\/","title":{"rendered":"AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature"},"content":{"rendered":"\n

Prefer to read rather than watch?<\/strong><\/h3>\n\n\n\n

Read our blog <\/a>which shares the key insights from the discussion.<\/p>\n\n\n\n

When AI Produces Hundreds of Answers: Turning Insight into Action<\/strong><\/p>\n\n\n\n

AI-driven workflows can identify hundreds of potential therapeutic targets in minutes.<\/p>\n\n\n\n

But quantity doesn\u2019t equal confidence.<\/p>\n\n\n\n

A target may appear statistically compelling while hiding critical biological risks, tissue-specific safety concerns or clinical limitations that only emerge through deeper investigation.<\/p>\n\n\n\n

The question isn\u2019t: \u00ab\u00a0Can AI find targets?\u00a0\u00bb<\/em><\/p>\n\n\n\n

It\u2019s: \u00ab\u00a0How do you identify the targets worth pursuing and eliminate those that aren\u2019t?\u00a0\u00bb<\/em><\/p>\n\n\n\n

In this 45-minute fireside chat, experts from Sygnature Discovery and QIAGEN Digital Insights<\/a> share their perspectives on the evolving role of AI in target identification. Drawing on their combined expertise in bioinformatics, pathway analysis, translational biology, and drug discovery, the panel explores the practical challenges of moving from AI-generated target lists to confident, evidence-based decisions.<\/p>\n\n\n\n

Through real-world examples and discussion, viewers will gain insights into how scientific expertise, experimental validation, and data-driven analysis can be combined to improve target prioritization, reduce risk, and support more effective drug discovery programs.<\/p>\n\n\n\n

Register to watch this webinar on demand<\/a><\/strong><\/p>\n\n\n\n

In This Webinar You\u2019ll Learn<\/strong><\/p>\n\n\n\n

\n
\n \n \n<\/path>\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Beyond AI Rankings<\/h3>\n\n\n\n

Why highly-ranked targets can fail when biological context is missing.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n<\/path>\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Human Expertise in the Loop<\/h3>\n\n\n\n

How multidisciplinary teams challenge, validate and refine AI-generated insights.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n<\/path>\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Making AI Explainable<\/h3>\n\n\n\n

What scientists need to see before committing to experimental validation.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n<\/path>\n<\/svg>\n\n \n <\/section>\n\n\n
\n

From Targets to Pathways<\/h3>\n\n\n\n

Why understanding pathway biology can reveal opportunities AI alone may miss.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n<\/path>\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Fail Faster<\/h3>\n\n\n\n

How leading teams design workflows that identify risks early and avoid costly dead ends.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

Key Discussion Topics<\/strong><\/h3>\n\n\n\n